Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation
Authors:
- D. FrappazDFD. Frappaz
- V. EdelineVEV. Edeline
- for the SFOP GroupFGfor the SFOP Group
- 1 April 2000
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 34 (4) , 237-241
Abstract
In children over 1 year of age with metastatic neuroblastoma, clearance of metaiodobenzylguanidine (MIBG) skeletal uptake after four courses of induction chemotherapy is one of the most powerful prognostic factors. How subjective is quantification of MIBG uptake, and can earlier MIBG scintigraphy separate good and bad responders? The data from 47 patients who received uniform induction therapy were reviewed. A novel scoring system of MIBG update intensity was proposed. Initial, intermediate (after two courses), and final (after four courses) intensities were scored (0 to 21 points) independently by six different observers. The initial global score and the relative score (calculated by dividing the global score after two courses by the initial score) were compared to the final score. Good responders were those who scored 0 at final MIBG. Between two observers, the correlation coefficient for the global score was superior to 0.80, in nine of ten comparisons established between observers 1–5. The initial score did not predict the final score insofar as only nine of fourteen patients with low initial scores were good responders. The relative score also failed to predict outcome; only six of ten patients with favorable relative score (i.e., <20%), were good responders. This scoring system is reliable and may be used in multicentric trials. However, both initial and relative scores failed to predict final outcome. Thus, intermediate MIBG may be omitted during induction therapy assessment. Med. Pediatr. Oncol. 34:237–241, 2000.Keywords
This publication has 13 references indexed in Scilit:
- NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.Journal of Clinical Oncology, 1997
- Metastatic neuroblastoma in children older than one year: Prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring systemCancer, 1996
- Observer variation in the interpretation of bone scintigraphyJournal of Clinical Epidemiology, 1996
- Evaluation of CD44 prognostic value in neuroblastoma: Comparison with the other prognostic factorsEuropean Journal of Cancer, 1995
- A new 123I-MIBG whole body scan scoring method—Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastomaEuropean Journal of Cancer, 1995
- Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation.Journal of Clinical Oncology, 1993
- Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.Journal of Clinical Oncology, 1993
- Neuroblastoma: Effect of genetic factors on prognosis and treatmentCancer, 1992
- I‐131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapseMedical and Pediatric Oncology, 1988
- Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?Journal of Clinical Oncology, 1987